DrugWonks on Twitter
Tweets by @PeterPittsDrugWonks on Facebook
CMPI Videos
Video Montage of Third Annual Odyssey Awards Gala Featuring Governor Mitch Daniels, Montel Williams, Dr. Paul Offit and CMPI president Peter Pitts
Indiana Governor Mitch Daniels
Montel Williams, Emmy Award-Winning Talk Show Host
Paul Offit, M.D., Chief of the Division of Infectious Diseases and the Director of the Vaccine Education Center at the Children’s Hospital of Philadelphia, for Leadership in Transformational Medicine
CMPI president Peter J. Pitts
CMPI Web Video: "Science or Celebrity"
Tabloid Medicine
Check Out CMPI's Book
Physician Disempowerment:
A Transatlantic Malaise
Edited By: Peter J. Pitts
Download the E-Book Version Here
A Transatlantic Malaise
Edited By: Peter J. Pitts
Download the E-Book Version Here
CMPI Events
Donate
CMPI Reports
Blog Roll
Alliance for Patient Access
Alternative Health Practice
AHRP
Better Health
BigGovHealth
Biotech Blog
BrandweekNRX
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
CNEhealth.org
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
eDrugSearch
Envisioning 2.0
EyeOnFDA
FDA Law Blog
Fierce Pharma
fightingdiseases.org
Fresh Air Fund
Furious Seasons
Gooznews
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
IgniteBlog
In the Pipeline
In Vivo
Instapundit
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
KevinMD
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
Medrants
More than Medicine
National Review
Neuroethics & Law
Newsbusters
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
PAL
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmablogger
Pharmacology Corner
Pharmagossip
Pharmamotion
Pharmalot
Pharmaceutical Business Review
Piper Report
Polipundit
Powerline
Prescription for a Cure
Public Plan Facts
Quackwatch
Real Clear Politics
Remedyhealthcare
Shark Report
Shearlings Got Plowed
StateHouseCall.org
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
TortsProf
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog
AHRP
Better Health
BigGovHealth
Biotech Blog
BrandweekNRX
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
CNEhealth.org
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
eDrugSearch
Envisioning 2.0
EyeOnFDA
FDA Law Blog
Fierce Pharma
fightingdiseases.org
Fresh Air Fund
Furious Seasons
Gooznews
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
IgniteBlog
In the Pipeline
In Vivo
Instapundit
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
KevinMD
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
Medrants
More than Medicine
National Review
Neuroethics & Law
Newsbusters
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
PAL
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmablogger
Pharmacology Corner
Pharmagossip
Pharmamotion
Pharmalot
Pharmaceutical Business Review
Piper Report
Polipundit
Powerline
Prescription for a Cure
Public Plan Facts
Quackwatch
Real Clear Politics
Remedyhealthcare
Shark Report
Shearlings Got Plowed
StateHouseCall.org
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
TortsProf
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog
DrugWonks Blog
04/30/2007 06:26 AM |
Last week Andy von Eschenbach commented that "We all talk about change -- but usually change in somebody else." Keeping that in mind, have a look at today's lead editorial from the Washington Times ...
The recent food scares
Watching the never-ending hearings Democrats are now holding on the Food and Drug Administration reminds us of Al Capone's assertion that "I have built my organization on fear." Indeed, a day has not gone by that a show trial has not been held claiming that our drugs are unsafe, and, now that our food is poisoned because the agency is compromised by a cozy relationship between the industries, it is supposed to police and the regulators themselves. The four most common bacteria, including salmonella and e-coli, contribute to about 5,000 deaths each year and cost our economy nearly $7 billion annually. The recent spate of food-related problems -- ranging from spinach contamination to a peanut butter recall and now to the discovery that a poisonous additive may be in animal food imported from China -- underscores the importance of ensuring the safety of the nation's food supply.
But adding more bureaucrats, or, alternatively, threatening FDA officials with salary cuts, are not the responses our nation needs. The recent problems have a common theme: They are the product of a more global and industrialized process of food production that allows pathogens to spread and emerge more rapidly than was the case 20 years ago. Better tools for identifying and detecting outbreaks and contaminants in the food supply in real-time fashion are available but not in widespread use at this time.
The United States has a surveillance system in place for detecting emerging pathogens called Foodnet. In turn, it is supported by a series of labs called PulseNet that subtypes and electronically compares pathogens as they are discovered and detected. This network needs to be upgraded and enhanced.
Moreover, both the FDA and the Department of Agriculture should clear the path for the use of nanotechnology devices that will be able to detect toxins, pathogens and chemicals in the production and packaging of foods on the spot. Such devices could monitor the presence of such materials without on-site inspection. Also, they could be used to alert consumers to tainted products at the retail level.
Unfortunately, Congress is more interested in building up the size of government through fear-mongering rather than insuring the public safety with advances in technology. Capone would be proud.
Where's Elliot Ness when we need him? Read More & Comment...
The recent food scares
Watching the never-ending hearings Democrats are now holding on the Food and Drug Administration reminds us of Al Capone's assertion that "I have built my organization on fear." Indeed, a day has not gone by that a show trial has not been held claiming that our drugs are unsafe, and, now that our food is poisoned because the agency is compromised by a cozy relationship between the industries, it is supposed to police and the regulators themselves. The four most common bacteria, including salmonella and e-coli, contribute to about 5,000 deaths each year and cost our economy nearly $7 billion annually. The recent spate of food-related problems -- ranging from spinach contamination to a peanut butter recall and now to the discovery that a poisonous additive may be in animal food imported from China -- underscores the importance of ensuring the safety of the nation's food supply.
But adding more bureaucrats, or, alternatively, threatening FDA officials with salary cuts, are not the responses our nation needs. The recent problems have a common theme: They are the product of a more global and industrialized process of food production that allows pathogens to spread and emerge more rapidly than was the case 20 years ago. Better tools for identifying and detecting outbreaks and contaminants in the food supply in real-time fashion are available but not in widespread use at this time.
The United States has a surveillance system in place for detecting emerging pathogens called Foodnet. In turn, it is supported by a series of labs called PulseNet that subtypes and electronically compares pathogens as they are discovered and detected. This network needs to be upgraded and enhanced.
Moreover, both the FDA and the Department of Agriculture should clear the path for the use of nanotechnology devices that will be able to detect toxins, pathogens and chemicals in the production and packaging of foods on the spot. Such devices could monitor the presence of such materials without on-site inspection. Also, they could be used to alert consumers to tainted products at the retail level.
Unfortunately, Congress is more interested in building up the size of government through fear-mongering rather than insuring the public safety with advances in technology. Capone would be proud.
Where's Elliot Ness when we need him? Read More & Comment...
04/30/2007 05:03 AM |
The pun couldn't be more perverse or the message more clear -- men in high public office need to keep it zipped. The fact that Mr. Tobias represented our nation on AIDS issues (like abstinence) makes this even more unfortunate. Who vetted this guy anyway? On a personal note, I served on a United Way of Indiaia committee with Tobias when he was at the helm of Eli Lilly. Hs good works were well known. But now he will be remembered for other, less noble deeds. Shameful. Read More & Comment...
04/27/2007 03:31 PM |
From the Moscow Times ...
The State Duma will examine plans to stiffen penalties for manufacturers and distributors of counterfeit pharmaceuticals Friday, one of the sponsors of the proposed bill said Thursday.
"It will be the first reading of a bill to create a new statute in the legal code covering the manufacture, intent to supply, supply, storage, transportation and importation of counterfeit pharmaceuticals," said Pyotr Shelishch, a member of the Duma's Legislation Committee.
Counterfeit medicine is a serious problem on the Russian market, Shelishch said.
"It's difficult to say what the amount of counterfeit drugs is, but estimates range from fractions of a percentage up to 10 percent," he said. The country's pharmaceutical market is worth around $10.7 billion, according to estimates by industry consultant Pharmexpert
According to the new proposals, the minimum penalty would rise to 500,000 rubles ($20,000) and the maximum penalty would be a 15-year prison term, Shelishch said.
"The maximum sentence would be applicable if it led to the deaths of two or more people," he said.
The new measures come as a result of glaring shortcomings in existing legislation, lawmakers and analysts said.
"I welcome this new move, as we still do not have any law to punish those people that produce counterfeit drugs in Russia," said Nikolai Demidov, general director of Pharmexpert.
In November, pharmaceuticals firm Bryntsalov-A was handed a 40,000 ruble fine after being found guilty of offenses including the improper storage of drugs.
Manufacturers welcomed the proposed legislation but said new laws needed to be backed up by tougher action. "Any changes in legislation should be followed by relevant enforcement measures. Legislative amendments are meaningless without strong support of control activities from executive authorities," a GlaxoSmithKline Russia spokesman said.
"We would like to see examples being made where those found to knowingly trade in counterfeit medicines are prosecuted and receive meaningful penalties," the spokesman said. "We would also like to see an increase in checks on pharmacies and warehouses."
With international standards such as the good manufacturing practices code as yet not obligatory in Russia, Demidov said overall production control needed to be sharpened.
The prevalence of counterfeit medicine in the country has consistently been one of the major factors hampering Russia's entry into the World Trade Organization.
"Of course we are thinking first of all about our citizens, but if these measures help facilitate Russia's entry into the WTO, then that is also positive," Shelishch said.
The urgency of these requirements makes it likely that the legislative changes will be passed by the end of the year, Demidov said.
"I hope that this law will be adopted not later than September. I am linking this with the WTO membership bid," he said.
It's a good start, but the Russian government can still Duma. (Get it.) Read More & Comment...
The State Duma will examine plans to stiffen penalties for manufacturers and distributors of counterfeit pharmaceuticals Friday, one of the sponsors of the proposed bill said Thursday.
"It will be the first reading of a bill to create a new statute in the legal code covering the manufacture, intent to supply, supply, storage, transportation and importation of counterfeit pharmaceuticals," said Pyotr Shelishch, a member of the Duma's Legislation Committee.
Counterfeit medicine is a serious problem on the Russian market, Shelishch said.
"It's difficult to say what the amount of counterfeit drugs is, but estimates range from fractions of a percentage up to 10 percent," he said. The country's pharmaceutical market is worth around $10.7 billion, according to estimates by industry consultant Pharmexpert
According to the new proposals, the minimum penalty would rise to 500,000 rubles ($20,000) and the maximum penalty would be a 15-year prison term, Shelishch said.
"The maximum sentence would be applicable if it led to the deaths of two or more people," he said.
The new measures come as a result of glaring shortcomings in existing legislation, lawmakers and analysts said.
"I welcome this new move, as we still do not have any law to punish those people that produce counterfeit drugs in Russia," said Nikolai Demidov, general director of Pharmexpert.
In November, pharmaceuticals firm Bryntsalov-A was handed a 40,000 ruble fine after being found guilty of offenses including the improper storage of drugs.
Manufacturers welcomed the proposed legislation but said new laws needed to be backed up by tougher action. "Any changes in legislation should be followed by relevant enforcement measures. Legislative amendments are meaningless without strong support of control activities from executive authorities," a GlaxoSmithKline Russia spokesman said.
"We would like to see examples being made where those found to knowingly trade in counterfeit medicines are prosecuted and receive meaningful penalties," the spokesman said. "We would also like to see an increase in checks on pharmacies and warehouses."
With international standards such as the good manufacturing practices code as yet not obligatory in Russia, Demidov said overall production control needed to be sharpened.
The prevalence of counterfeit medicine in the country has consistently been one of the major factors hampering Russia's entry into the World Trade Organization.
"Of course we are thinking first of all about our citizens, but if these measures help facilitate Russia's entry into the WTO, then that is also positive," Shelishch said.
The urgency of these requirements makes it likely that the legislative changes will be passed by the end of the year, Demidov said.
"I hope that this law will be adopted not later than September. I am linking this with the WTO membership bid," he said.
It's a good start, but the Russian government can still Duma. (Get it.) Read More & Comment...
04/26/2007 02:39 PM |
"We have the possibility of getting a very, very powerful predictive test that measures your risk of developing type 2 diabetes," said Dr. Kari Stefansson, president and CEO of Icelandic company deCODE genetics Inc.
Meanwhile AHIP wants the FDA to impose more costs and regulation to get approval of such predictive tests but proposes spending $8 billion a year to make one size fits all recommendations on which diabetes drugs Medicare should pay for. Read More & Comment...
Meanwhile AHIP wants the FDA to impose more costs and regulation to get approval of such predictive tests but proposes spending $8 billion a year to make one size fits all recommendations on which diabetes drugs Medicare should pay for. Read More & Comment...
04/26/2007 06:09 AM |
Another story in the WSJ today about a "study" about conficts in medicine cooked up by people who have conflicts themselves, at least in the way they define conflicts. Blumenthal and Rothman's IMAP gets money from the liberal Soros whose drug companies aggressively marketed testosterone products off-label and works with Community Catalyst, which rakes in money suing drug companies through its Prescription Drug Access Litigation Project.
At least the story gets in one good quote from Tom Stossel who said it best ""If a physician can be influenced into prescribing certain drugs just because he had pizza with a pharmaceutical guy, then it's the fault of his training and not the drug company." Or his or herself.
In general, if I had a choice of doctors being "influenced" by pizza deliveries from drug reps or trial attorney funded front groups...guess which one I would choose?
Make that a pie with extra cheese.
http://content.nejm.org/cgi/content/full/356/17/1742 Read More & Comment...
At least the story gets in one good quote from Tom Stossel who said it best ""If a physician can be influenced into prescribing certain drugs just because he had pizza with a pharmaceutical guy, then it's the fault of his training and not the drug company." Or his or herself.
In general, if I had a choice of doctors being "influenced" by pizza deliveries from drug reps or trial attorney funded front groups...guess which one I would choose?
Make that a pie with extra cheese.
http://content.nejm.org/cgi/content/full/356/17/1742 Read More & Comment...
04/25/2007 02:07 PM |
Brazil is now demanding that Merck lower the price for its HIV drug Efavirenz to what it is being sold in Thailand. (From $1.59 to 65 cents) If Merck does not agree (which it will) then Brazil's health minister will seek a compulsory license for the drug.
Again, unless companies come up with a long term strategy to deal with pricing in emerging or middle markets, NGOs will continue to use the CL route to ratchet down the price of ALL medicines.
No way to run a business. Read More & Comment...
Again, unless companies come up with a long term strategy to deal with pricing in emerging or middle markets, NGOs will continue to use the CL route to ratchet down the price of ALL medicines.
No way to run a business. Read More & Comment...
04/25/2007 01:55 PM |
America's Health Insurance Plans that the Center for Medicare and Medicaid Services be “given explicit authority by Congress to us available data on comparative effectiveness and cost-effectiveness in determining in coverage policies. Similarly CMS should be empowered to set its reimbursement rates for new technologies more in alignment with added (for marginal) value of a new technology over established alternatives.“
AHIP's Steve Pearson claims that NICE cost effectiveness decisions have a high level of acceptance by physicians which are due in large part to the "very early and explicit attention to the quality of the data they use. NICE has earned a well-deserved reputation for methodological rigor, transparency, and an ability to learn."
http://www.cmwf.org/publications/publications_show.htm?doc_id=252181
Read Peter's post for a reality check.
AHIP is sucking up to the D's in Congress plain and simple. And it is working with the Commonwealth Fund to enact rationing of new medicines and devices (check out what AHIP wants the FDA to do on new device and diagnostic regulation!)
I thought AHIP had more sense and compassion. You can read the whole report that calls for the creation of a NICE like entity in America here:
http://www.ahip.org/content/pressrelease.aspx?docid=19476 Read More & Comment...
AHIP's Steve Pearson claims that NICE cost effectiveness decisions have a high level of acceptance by physicians which are due in large part to the "very early and explicit attention to the quality of the data they use. NICE has earned a well-deserved reputation for methodological rigor, transparency, and an ability to learn."
http://www.cmwf.org/publications/publications_show.htm?doc_id=252181
Read Peter's post for a reality check.
AHIP is sucking up to the D's in Congress plain and simple. And it is working with the Commonwealth Fund to enact rationing of new medicines and devices (check out what AHIP wants the FDA to do on new device and diagnostic regulation!)
I thought AHIP had more sense and compassion. You can read the whole report that calls for the creation of a NICE like entity in America here:
http://www.ahip.org/content/pressrelease.aspx?docid=19476 Read More & Comment...
04/25/2007 07:33 AM |
Whether it’s said in an American accent or a more refined British one, what's most important is to accent the truth – comparative effectiveness is bad medicine when you use healthcare technology assessment (HTA) tools (aka "Evidence-based Medicine") that misuse and misrepresent data derived from RCTs. Doing so yields results that budget managers want – regardless of whether or not it yields what’s best for the patient.
It’s the choice of short-term, short-sighted politicians.
Consider what’s going on in the UK.
The Association of the British Pharmaceutical is fighting proposals by the Office of Fair Trading to overhaul the pharmaceutical price regulation scheme so drugs companies will be forced to evaluate the benefit to the patient and the National Health Service when they set the prices.
Richard Barker, ABPI director-general, called the OFT's proposals "dangerous and anti-innovative". "The OFT has failed to understand the nature of scientific progress is step by step," he said, arguing that without a commercial incentive to introduce incremental improvements, more significant breakthroughs in new medicines would not take place.
He said the industry's two principal demands were to enhance the methods used for "health technology assessment", which would scrutinize the efficacy and cost benefits of new medicines; and to boost the often poor "uptake" of new medicines recommended by the National Institute for Clinical Excellence, the medicines advisory body.
His comments came ahead of hearings set to begin in the coming weeks by the Commons' health committee on the operation of the institute, which is studying why the agency's decisions are increasingly being questioned and whether public confidence in the organization is waning.
MPs will discuss the evaluation process and whether any particular groups are disadvantaged by the process, the speed of publishing guidance, the appeal system, comparison with the work of its Scottish counterpart, and implementation of its guidance.
Here’s the full story from the Financial Times:
http://www.ft.com/cms/s/88cd12b8-f2c8-11db-a454-000b5df10621.html Read More & Comment...
It’s the choice of short-term, short-sighted politicians.
Consider what’s going on in the UK.
The Association of the British Pharmaceutical is fighting proposals by the Office of Fair Trading to overhaul the pharmaceutical price regulation scheme so drugs companies will be forced to evaluate the benefit to the patient and the National Health Service when they set the prices.
Richard Barker, ABPI director-general, called the OFT's proposals "dangerous and anti-innovative". "The OFT has failed to understand the nature of scientific progress is step by step," he said, arguing that without a commercial incentive to introduce incremental improvements, more significant breakthroughs in new medicines would not take place.
He said the industry's two principal demands were to enhance the methods used for "health technology assessment", which would scrutinize the efficacy and cost benefits of new medicines; and to boost the often poor "uptake" of new medicines recommended by the National Institute for Clinical Excellence, the medicines advisory body.
His comments came ahead of hearings set to begin in the coming weeks by the Commons' health committee on the operation of the institute, which is studying why the agency's decisions are increasingly being questioned and whether public confidence in the organization is waning.
MPs will discuss the evaluation process and whether any particular groups are disadvantaged by the process, the speed of publishing guidance, the appeal system, comparison with the work of its Scottish counterpart, and implementation of its guidance.
Here’s the full story from the Financial Times:
http://www.ft.com/cms/s/88cd12b8-f2c8-11db-a454-000b5df10621.html Read More & Comment...
04/25/2007 06:59 AM |
There is an old joke about the definition of chutzpah being someone who kills his parents and then asks for mercy from the judge because he's an orphan.
Now we have the journalist equivalent. Alex Berenson has an article in today's NYT: "US Wonders If Drug Data Was Accurate." You might recall Berenson helped ferret documents in violation of a court order to help build a biased case against Eli Lilly about well known side effects about Zyprexa and who was slammed by Judge Harvey Weinstein for doing so. And now he is writing about Zyprexa using the same documents he stole. Once again, Berenson uses the "one paper out of several thousands of documents" approach to depict Lilly as a criminal corporation.
And then at the end of the article Berenson writes: "A federal judge has criticized The Times for violating a protective order that covered the documents."
C'mon Alex we can be more accurate. We have the actual transcript describing YOUR behavior without violating the protective order. Didn't Judge Weinstein describe what you did as conspiring " to obtain and publish documents in knowing violation of a court order not to do so, and that they executed the conspiracy using other people as their agents in crime."
And as another report noted, Weinstein further described the actions of the men as "illegal," "stealing," a "brazen flouting" of his order and, in the case of Berenson, "reprehensible." He took occasion to quote from a 2004 version of the Times' handbook on ethical journalism: "Staff members must obey the law in pursuit of news."
On the heels of intense criticism of the NYT coverage of the Duke rape case and the paper's falling earnings, the Berenson reporting is another example of the Times decline. Read More & Comment...
Now we have the journalist equivalent. Alex Berenson has an article in today's NYT: "US Wonders If Drug Data Was Accurate." You might recall Berenson helped ferret documents in violation of a court order to help build a biased case against Eli Lilly about well known side effects about Zyprexa and who was slammed by Judge Harvey Weinstein for doing so. And now he is writing about Zyprexa using the same documents he stole. Once again, Berenson uses the "one paper out of several thousands of documents" approach to depict Lilly as a criminal corporation.
And then at the end of the article Berenson writes: "A federal judge has criticized The Times for violating a protective order that covered the documents."
C'mon Alex we can be more accurate. We have the actual transcript describing YOUR behavior without violating the protective order. Didn't Judge Weinstein describe what you did as conspiring " to obtain and publish documents in knowing violation of a court order not to do so, and that they executed the conspiracy using other people as their agents in crime."
And as another report noted, Weinstein further described the actions of the men as "illegal," "stealing," a "brazen flouting" of his order and, in the case of Berenson, "reprehensible." He took occasion to quote from a 2004 version of the Times' handbook on ethical journalism: "Staff members must obey the law in pursuit of news."
On the heels of intense criticism of the NYT coverage of the Duke rape case and the paper's falling earnings, the Berenson reporting is another example of the Times decline. Read More & Comment...
04/24/2007 09:07 PM |
Pfizer's New combo drug-diagnostic for HIV got through the FDA Adcomm... I still wonder what prompted the FDA to dump all the safety concerns ahead of the commitee meeting?
http://blogs.wsj.com/health/2007/04/24/pfizer-aids-drug-gets-fda-panel-support/ Read More & Comment...
http://blogs.wsj.com/health/2007/04/24/pfizer-aids-drug-gets-fda-panel-support/ Read More & Comment...
04/24/2007 02:40 PM |
The FDA announced today that all supplements and products derived from kryptonite would have a black box warning. Dr. David Graham had pressured the agency after noting that the presence of kryptonite would pose a serious and life threatening danger to Superman, Supergirl and other survivors of the planet Krypton. Graham had been pushing Congress to expand it's drug safety program to move beyond "merely planetary surveillance activities" and into galactic exploration of pharmacovigilance matters. The FDA said in a press release " this pilot project is part of our effort to develop a global and indeed galactic risk management program." The agency had planned to establish this program in partnership with Luthor Industries and the Justice League of America but was attacked by members of Congress for being too "cozy" with special interests. Read More & Comment...
04/24/2007 12:46 PM |
When it comes to what this Congress is trying to do to the public health, we refuse to sit by and take a postion of, er, non-intereference.
Here's a new piece from today's edition of the Chicago Tribune:
http://www.chicagotribune.com/news/opinion/chi-0704230346apr24,0,7088012.story?coll=chi-newsopinioncommentary-hed
Hopefully some prominent Chicago officials (like Barack Obama and Rahm Emanuel) will see this and see the light. But we'll keep our expectations realistic and just hope they see it. Read More & Comment...
Here's a new piece from today's edition of the Chicago Tribune:
http://www.chicagotribune.com/news/opinion/chi-0704230346apr24,0,7088012.story?coll=chi-newsopinioncommentary-hed
Hopefully some prominent Chicago officials (like Barack Obama and Rahm Emanuel) will see this and see the light. But we'll keep our expectations realistic and just hope they see it. Read More & Comment...
04/24/2007 10:28 AM |
Again, I am not making this up.....
New breakthrough research demonstrates for the first time that spending 5 minutes with a drug rep alters the subconscious mind of doctors in subtle ways, causing them to prescribe drugs that no one really need or wants or even uses.
The survey of 116 visits to 97 doctors found that after a five minute "session" with a drug rep, doctors were 46 percent more likely to prescribe a drug or recommend it to their colleagues.
One of the author's of this groundbreaking study, Dr. Michael Steinman of the San Francisco Veteran's Affairs Hospital said: "The remarkable thing is how effective a very brief visit by a drug representative -- most often less than five minutes -- can be in influencing physicians' choices to use a drug for an unapproved indication,"
Besides free drug samples, salespeople often bring gifts, lunch for the doctor or office staff, new pens and coffee mugs. "The doctor feels subtly, even subconsciously, indebted to the representative," Steinman said.
The study appears in the April 24, 2007 issue of PLoS Medicine. Co-authors of the study were G. Michael Harper, MD, Mary-Margaret Chren, MD, and C. Seth Landefeld, MD, of SFVAMC and UCSF.
Steinman, Landefeld, and Chren served as unpaid expert witnesses for the plaintiff in the litigation from which the source data for the study was obtained.
What a surprise.
The study was supported by funds from the Veterans Health Administration, the National Institute on Arthritis and Musculoskeletal and Skin Diseases, the National Institute on Aging, the John A. Hartford Foundation, and the California Tobacco-Related Disease Research Programs.
What is government money doing supporting such crap? Read More & Comment...
New breakthrough research demonstrates for the first time that spending 5 minutes with a drug rep alters the subconscious mind of doctors in subtle ways, causing them to prescribe drugs that no one really need or wants or even uses.
The survey of 116 visits to 97 doctors found that after a five minute "session" with a drug rep, doctors were 46 percent more likely to prescribe a drug or recommend it to their colleagues.
One of the author's of this groundbreaking study, Dr. Michael Steinman of the San Francisco Veteran's Affairs Hospital said: "The remarkable thing is how effective a very brief visit by a drug representative -- most often less than five minutes -- can be in influencing physicians' choices to use a drug for an unapproved indication,"
Besides free drug samples, salespeople often bring gifts, lunch for the doctor or office staff, new pens and coffee mugs. "The doctor feels subtly, even subconsciously, indebted to the representative," Steinman said.
The study appears in the April 24, 2007 issue of PLoS Medicine. Co-authors of the study were G. Michael Harper, MD, Mary-Margaret Chren, MD, and C. Seth Landefeld, MD, of SFVAMC and UCSF.
Steinman, Landefeld, and Chren served as unpaid expert witnesses for the plaintiff in the litigation from which the source data for the study was obtained.
What a surprise.
The study was supported by funds from the Veterans Health Administration, the National Institute on Arthritis and Musculoskeletal and Skin Diseases, the National Institute on Aging, the John A. Hartford Foundation, and the California Tobacco-Related Disease Research Programs.
What is government money doing supporting such crap? Read More & Comment...
04/23/2007 09:12 AM |
Download file
Here's a link to Steve Usdin's superior article on FDA's Arcoxia attitude: Read More & Comment...
Here's a link to Steve Usdin's superior article on FDA's Arcoxia attitude: Read More & Comment...
04/23/2007 08:08 AM |
The Thai dictatorship clearly has Abbott in is sights. Working hand in glove with NGOs it clearly picked a fight over the price of its HIV drugs to distract attention over the suspension of civil liberties. It is disturbing to see Oxfam -- which boycotts Israel over so-called human rights abuses -- working with Thailand's military junta to demonize drug companies yet again and get away with it. But that is how the media and most of the world sees things. So ultimately Abbott had no choice but to cave, at least for now.
Long term, drug companies need to rethink their approach to emerging markets. Time and the wealth are on the side of innovation and property rights, not the thugs and NGOs who prop them up. They would do well to increase investment in global health policy, entrepreneurship in middle markets, and support partnerships with people interested in delivering new products throughout the world at market relevant prices. Read More & Comment...
Long term, drug companies need to rethink their approach to emerging markets. Time and the wealth are on the side of innovation and property rights, not the thugs and NGOs who prop them up. They would do well to increase investment in global health policy, entrepreneurship in middle markets, and support partnerships with people interested in delivering new products throughout the world at market relevant prices. Read More & Comment...
04/23/2007 07:35 AM |
AP's Andrew Bridges reports today that
" Health officials repeated safety concerns about an experimental group of HIV drugs Friday, days before government advisers will recommend whether the first drug from the class merits approval.
Pfizer Inc. seeks Food and Drug Administration approval for maraviroc, potentially the first in a novel group of drugs to fight HIV, the virus that causes AIDS. Pfizer proposes marketing maraviroc as Celsentri.
Pfizer believes there is a clear unmet need for new drugs to fight HIV in patients for whom other, older drugs no longer work. Celsentri is unlike any other HIV medicines now on the market in that it targets the cells of patients and not the virus itself.
The FDA has scheduled a Tuesday meeting of outside experts to discuss Pfizer's application for approval. The FDA has asked the experts whether Celsentri, if approved, would require special labeling or if further study of the drug's safety is needed before it can be sold. FDA also asked whether the drug should be studied further in women and blacks."
Is this a strategic attempt to get the "bad news" out ahead of the Adcomm meeting or an effort to scuttle the drug in order to avoid looking bad? CCR5 inhibitors have been associated with an increased risk of liver damage and lymphoma but I don't know what that risk is relative to other drugs such as tylenol or other viruses left untreated. More worrisome perhaps: Maraviroc not only targets specific cells, but it will be marketed with a protein assay that will identify which patients that are high responders. Personalized medicine. Which means that the risk benefit profile will be higher still. I don't get this need for studying African Americans and women when you have a genetic test. Why not study Ashkenazic Jews still suffering from last night's Yankee game who live in New Jersey while your at it?
A first in class personalized medicine for a fatal disease and still the agency is screwing around with safety issues. Just how high does the bar have to be to get a drug approved? Read More & Comment...
" Health officials repeated safety concerns about an experimental group of HIV drugs Friday, days before government advisers will recommend whether the first drug from the class merits approval.
Pfizer Inc. seeks Food and Drug Administration approval for maraviroc, potentially the first in a novel group of drugs to fight HIV, the virus that causes AIDS. Pfizer proposes marketing maraviroc as Celsentri.
Pfizer believes there is a clear unmet need for new drugs to fight HIV in patients for whom other, older drugs no longer work. Celsentri is unlike any other HIV medicines now on the market in that it targets the cells of patients and not the virus itself.
The FDA has scheduled a Tuesday meeting of outside experts to discuss Pfizer's application for approval. The FDA has asked the experts whether Celsentri, if approved, would require special labeling or if further study of the drug's safety is needed before it can be sold. FDA also asked whether the drug should be studied further in women and blacks."
Is this a strategic attempt to get the "bad news" out ahead of the Adcomm meeting or an effort to scuttle the drug in order to avoid looking bad? CCR5 inhibitors have been associated with an increased risk of liver damage and lymphoma but I don't know what that risk is relative to other drugs such as tylenol or other viruses left untreated. More worrisome perhaps: Maraviroc not only targets specific cells, but it will be marketed with a protein assay that will identify which patients that are high responders. Personalized medicine. Which means that the risk benefit profile will be higher still. I don't get this need for studying African Americans and women when you have a genetic test. Why not study Ashkenazic Jews still suffering from last night's Yankee game who live in New Jersey while your at it?
A first in class personalized medicine for a fatal disease and still the agency is screwing around with safety issues. Just how high does the bar have to be to get a drug approved? Read More & Comment...
04/23/2007 06:54 AM |
Lots of folks exercising their right to free speech over the issue of limiting free speech, aka: DTC advertising. The latest is the legislative attempt to give the FDA authority to ban advertising for the first two years after a drug is approved.
Here’s Senator Kennedy’s perspective:
"What we are looking at is the very rare circumstance. It would be used in the most limited kinds of circumstances, where the FDA … wants to give approval for a drug but is not sure and fears advertising will lead to massive use of the drugs.â€
But FDA already negotiates such circumstances. That’s the key word, “negotiate.†And it’s not a finesse. Minus that word it’s … unconstitutional.
And there are many people, far less holy than Senator Kennedy, who see this as the first step towards banning pharmaceutical advertising altogether.
Consider what a Consumer Reports analyst said, "We don't know, and we won't know, how truly safe a drug is until it's been used in millions of people. The real testing of these drugs takes place after a pill hits the market, and that's why the advertising needs to be regulated."
Drugwonks does not believe that less information makes anything or anyone safter.
Make no mistake – this is a battle not only over the future role of the empowered health care consumer – but for the First Amendment.
Others are now saying, based on this new negative momentum, that DTC television ads will need to be more than one minute long to appropriately convey fair balance and adequate provision.
But it’s not a question of the time – it’s a question of the presentation. Can ads do a better job properly balancing risk and benefit? Most certainly. But it’s not necessarily a question of “more†as much as it is a question of “better.†And that means the FDA and industry (along with their advertising agencies) need better social science to determine how to best communicate such information to consumers.
Sounds like a good opening assignment for the agency’s new advisory committee on risk communications.
If we truly want to create a situation where our medicines are “safer†we must learn how to better communicate risk and benefit – not limit it.
Otherwise the empowered health care consumer might very well be gone in 60 seconds. Read More & Comment...
Here’s Senator Kennedy’s perspective:
"What we are looking at is the very rare circumstance. It would be used in the most limited kinds of circumstances, where the FDA … wants to give approval for a drug but is not sure and fears advertising will lead to massive use of the drugs.â€
But FDA already negotiates such circumstances. That’s the key word, “negotiate.†And it’s not a finesse. Minus that word it’s … unconstitutional.
And there are many people, far less holy than Senator Kennedy, who see this as the first step towards banning pharmaceutical advertising altogether.
Consider what a Consumer Reports analyst said, "We don't know, and we won't know, how truly safe a drug is until it's been used in millions of people. The real testing of these drugs takes place after a pill hits the market, and that's why the advertising needs to be regulated."
Drugwonks does not believe that less information makes anything or anyone safter.
Make no mistake – this is a battle not only over the future role of the empowered health care consumer – but for the First Amendment.
Others are now saying, based on this new negative momentum, that DTC television ads will need to be more than one minute long to appropriately convey fair balance and adequate provision.
But it’s not a question of the time – it’s a question of the presentation. Can ads do a better job properly balancing risk and benefit? Most certainly. But it’s not necessarily a question of “more†as much as it is a question of “better.†And that means the FDA and industry (along with their advertising agencies) need better social science to determine how to best communicate such information to consumers.
Sounds like a good opening assignment for the agency’s new advisory committee on risk communications.
If we truly want to create a situation where our medicines are “safer†we must learn how to better communicate risk and benefit – not limit it.
Otherwise the empowered health care consumer might very well be gone in 60 seconds. Read More & Comment...
04/20/2007 09:43 AM |
I agree with Bob Goldberg's recent post refering to the uses of anti-psychotics and how they might have helped control the Virginia Tech killer, if they were taken, a big IF.. I also believe that universities should be able to mandate ongoing psychiatric care for someone like this - "if you don't like it, then leave the university."
which is not the say that a treating psychiatrist would have been able to intervene in time. It is not for sure that the killer would have revealed his plan beforehand. But if he had, then the treating psychiatrist would have had an obligation to admit him for acute homicidal ideation. It is also obvious that a person like this, with such a known psych history, especially with violent ideation, should not be allowed to purchase guns, and certainly computers could be used to create such a useful databank that gun stores could adhere to.
There is another issue to address - one that I have written extensively about in my book False Alarm: the Truth About the Epidemic of Fear.
Namely that it is too easy to personalize what you see in the news, too easy to attach yourself voyeuristically to a crime like Columbine or this one and feel as if it is going to happen to you.
THis kind of fear is infectious, and the killer knew this, which was one of the reasons he may have chosed a Columbine-like model.
My friend Gary Baumgarten of Paltalk, formerly of CNN radio, has written about this fear factor today in his blog and cited my book.
http://www.paltalk.com/newstalk/msiegel_041907_archive.shtml#comments Read More & Comment...
which is not the say that a treating psychiatrist would have been able to intervene in time. It is not for sure that the killer would have revealed his plan beforehand. But if he had, then the treating psychiatrist would have had an obligation to admit him for acute homicidal ideation. It is also obvious that a person like this, with such a known psych history, especially with violent ideation, should not be allowed to purchase guns, and certainly computers could be used to create such a useful databank that gun stores could adhere to.
There is another issue to address - one that I have written extensively about in my book False Alarm: the Truth About the Epidemic of Fear.
Namely that it is too easy to personalize what you see in the news, too easy to attach yourself voyeuristically to a crime like Columbine or this one and feel as if it is going to happen to you.
THis kind of fear is infectious, and the killer knew this, which was one of the reasons he may have chosed a Columbine-like model.
My friend Gary Baumgarten of Paltalk, formerly of CNN radio, has written about this fear factor today in his blog and cited my book.
http://www.paltalk.com/newstalk/msiegel_041907_archive.shtml#comments Read More & Comment...
04/20/2007 08:35 AM |
She writes about a new drug designed to reduce the number of times a woman menstruates as if this were something drug companies were trying to take away from women or make them ashamed of. Why can't women choose to take control of their bodies? And incredibly THIS gets front page coverage at the NYT but not the article about the benefits of antidepressants. In fact the NYT did not assign a staff reporter to that important story. Disgusting.
http://www.nytimes.com/2007/04/20/health/20period.html?_r=1&oref=slogin Read More & Comment...
http://www.nytimes.com/2007/04/20/health/20period.html?_r=1&oref=slogin Read More & Comment...
04/20/2007 08:16 AM |
Why? Because they support Medicare advantage plans that give low income and chronically ill seniors more benefits at a cost with free drugs.... (Refer to Peter's post on Mark McClellan on how this happened..)
Krugman always writes like someone who finds it helpful to grind his axe on the necks of others. This piece is no different. Read all about it in his latest meltdown....
The Plot Against Medicare
"The plot against Social Security failed: President Bush's attempt to privatize the system crashed and burned when the public realized what he was up to. But the plot against Medicare is faring better: the stealth privatization embedded in the Medicare Modernization Act, which Congress literally passed in the dead of night back in 2003, is proceeding apace.
Worse yet, the forces behind privatization not only continue to have the G.O.P. in their pocket, but they have also been finding useful idiots within the newly powerful Democratic coalition. And it's not just politicians with an eye on campaign contributions. There's no nice way to say it: the NAACP and the League of United Latin American Citizens have become patsies for the insurance industry. " Read More & Comment...
Krugman always writes like someone who finds it helpful to grind his axe on the necks of others. This piece is no different. Read all about it in his latest meltdown....
The Plot Against Medicare
"The plot against Social Security failed: President Bush's attempt to privatize the system crashed and burned when the public realized what he was up to. But the plot against Medicare is faring better: the stealth privatization embedded in the Medicare Modernization Act, which Congress literally passed in the dead of night back in 2003, is proceeding apace.
Worse yet, the forces behind privatization not only continue to have the G.O.P. in their pocket, but they have also been finding useful idiots within the newly powerful Democratic coalition. And it's not just politicians with an eye on campaign contributions. There's no nice way to say it: the NAACP and the League of United Latin American Citizens have become patsies for the insurance industry. " Read More & Comment...
Social Networks
Please Follow the Drugwonks Blog on Facebook, Twitter, LinkedIn, YouTube & RSS
Add This Blog to my Technorati Favorites